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SUMMARY
Pubertal gynecomastia is a common condition observed in up to 65% of adolescent males. It is usually idiopathic and tends to
regress within 1–2 years. In this descriptive cross-sectional study, we investigated 25 adolescent males with prominent (>B3) and/or
persistent (>2 years) pubertal gynecomastia (P/PPG) to determine whether a hormonal/genetic defect might underline this condi-
tion. Endocrine investigation revealed the absence of hormonal disturbance for 18 boys (72%). Three patients presented Klinefelter
syndrome and three a partial androgen insensitivity syndrome (PAIS) as a result of p.Ala646Asp and p.Ala45Gly mutations of the
androgen receptor gene. The last patient showed a 17a-hydroxylase/17,20-lyase deﬁciency as a result of a compound heterozygous
mutation of the CYP17A1 gene leading to p.Pro35Thr(P35T) and p.Arg239Stop(R239X) in the P450c17 protein. Enzymatic activity was
analyzed: the mutant protein bearing the premature stop codon R239X showed a complete loss of 17a-hydroxylase and 17,20-lyase
activity. The mutant P35T seemed to retain 15–20% of 17a-hydroxylase and about 8–10% of 17,20-lyase activity. This work demon-
strates that P/PPG had an endocrine/genetic cause in 28% of our cases. PAIS may be expressed only by isolated gynecomastia as well
as by 17a-hydroxylase/17,20-lyase deﬁciency. Isolated P/PPG is not always a ‘physiological’ condition and should thus be investi-
gated through adequate endocrine and genetic investigations, even though larger studies are needed to better determine the real
prevalence of genetic defects in such patients.
INTRODUCTION
Pubertal gynecomastia is a common condition observed in
up to 65% of adolescent males. It results from a proliferation
in the glandular component of the breast, usually because a
transient relative imbalance between androgens and estrogens.
Pubertal gynecomastia is generally idiopathic and the breast
development is most often Tanner stage B2 (Tanner, 1962).
As it tends to regress within 1–2 years, pubertal gynecomastia
is considered as a benign condition and is regarded as a
part of normal development in pubertal males (Moore et al.,
1984).
If male breast development is over B3-B4, however, or if it per-
sists beyond 2–3 years, it may be the sign of an endocrine disor-
der, becoming a source of anxiety, self-consciousness,
embarrassment and severe psychological discomfort. In these
cases, determining the pathogenesis of pubertal gynecomastia
becomes mandatory.
In prominent and/or persistent pubertal gynecomastia (P/
PPG), the imbalance between the actions of androgens and
estrogens on male breast tissue may be attributable to an excess
of estrogen production, a decrease in androgen production or
action, or drugs. Estrogen-producing gonadal or adrenal tumors
and endocrine disorders thus have to be looked for, and patients
should be carefully questioned about drug use. Moreover, aro-
matase excess has recently been reported as a cause of P/PPG
(Fukami et al., 2011). Careful attention should be paid to the
patient’s morphotype and the testes should be examined to
exclude Klinefelter syndrome. An underlying disorder of sex dif-
ferentiation (DSD) such as partial androgen insensitivity syn-
drome (PAIS) or 17-b-hydroxysteroid dehydrogenase defect
should also be ruled out (Narula & Carlson, 2007). In addition,
environmental factors (Ma & Geffner, 2008) may be implicated.
Any of these conditions can cause excessive estrogen and/or
deﬁcient androgen activity.
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The aim of our study was to identify the causes of prominent/
persistent pubertal gynecomastia (P/PPG) in adolescent males,
particularly hormonal/genetic defects.
SUBJECTS AND METHODS
Patients
This descriptive cross-sectional study included all adolescent
males referred to the Pediatric Endocrine Clinic of the Montpel-
lier University Hospital between January 2011 and January 2014
for prominent and/or persistent pubertal gynecomastia. The
gynecomastia was evaluated by inspection and palpation as
described by (Braunstein, 2007) to distinguish between pseudog-
ynecomastia and true gynecomastia. The selection criteria
included the following: (i) Tanner pubertal status ≥2 (Tanner,
1962), (ii) lack of associated genital abnormalities, (iii) prominent
breast development (>B3), or (iv) persistence beyond 2 years. All
patients were asked about the use of drugs known to be involved
in the development of gynecomastia, i.e., spironolactone, cime-
tidine, ketoconazole, and antiandrogens (Deepinder & Braun-
stein, 2012), as well as the abuse of alcohol, marijuana, heroin,
amphetamines, and anabolic steroids (Goldman, 2010). Renal
and liver diseases were excluded for all patients.
Approval for this study was ﬁrst obtained from the appropriate
institutional review board and all patients gave signed informed
consent.
Anthropometric data
Standing height was measured to the nearest 0.1 cm with a
stadiometer (Seca, Semur-en-Auxois, France). Weight was mea-
sured on a weight scale with a precision of 0.1 kg. Body mass
index (BMI) was calculated as weight (kg) divided by the square
of height (m2). Grades of obesity were deﬁned on the basis of the
cut-off points used by the Obesity Task Force and derived from
Cole’s work (Cole et al., 2000). Pubertal development was
assessed by breast stages 1–5 of the Tanner classiﬁcation (Tan-
ner, 1962).
Radiological investigation
Bone age (BA) was determined using the Greulich and Pyle
method and testicular ultrasonography was performed for all
patients to exclude a testicular tumor.
Hormonal (biological) studies
The following hormones were measured at baseline for all
patients: estradiol (E2) (bioMerieux, Craponne, France), testos-
terone (T), D4-androstenedione (D4) (Immunotech, Marseille,
France), dehydroepiandrostenedione (DHEA) (Beckman Coulter,
Villepinte France), luteinizing hormone (LH), follicle-stimulating
hormone (FSH) (bioMerieux, Craponne, France), prolactin
(BRAHMS, Asnieres-sur-Seine, France), and thyroid-stimulating
hormone (TSH) (Roche, Boulogne-Billancourt, France).
The ACTH test was performed in one patient with the mea-
surement of cortisol (Roche), 17-OHP (CIS bio international, Gif-
sur-Yvette, France), progesterone (Roche), and DHEA before and
after stimulation.
Alpha-fetoprotein and human chorionic gonadotropin (hCG)
were evaluated for all patients (Roche).
The respective intra-assay and inter-assay coefﬁcients of
variation (CVs) were as follows: E2: 4.2 and 5.1%, T: 7 and <4%,
17-OHP: 2.7 and 2.9%, DHEA: 6.8 and 7.9%, Δ4: 5.6 and 6%, pro-
gesterone: 2.5 and 3.5%, LH: 4.8 and 6.6%, FSH: 4.9 and 3.5, PRL:
2.1 and 2.9%, TSH: 3 and 6%, and cortisol: 2.6 and 3.8%. The
detection limits were as follows: E2: 5 pg/mL, T: 0.04 ng/mL,
17-OHP: 0.1 ng/mL, DHEA: 0.3 ng/mL, Δ4: 0.04 ng/mL, proges-
terone: 0.09 nmol/L, LH: 0.1 U/L, FSH: 0.1 U/L, prolactin:
0.24 ng/mL, TSH: 0.005 lU/mL, and cortisol: 0.04 lg/dL.
Karyotyping
Karyotyping was performed when the clinical and biological
investigations suggested a genetic disorder; i.e., when the basal
FSH level was very high and/or the testicular volume was small.
It was also performed for a patient in whom we suspected a
steroidogenesis defect.
Molecular analysis
Androgen receptor (AR) gene
After polymerase chain reaction (PCR) ampliﬁcation of exons
1–8 of the AR using the Taq PCR Master Mix kit from Qiagen
(Courtaboeuf, France), we performed direct sequencing using
the BigDye terminator v1.1 kit (Applied Biosystems, Foster City,
CA, USA) and an ABI Prism310 Genetic Analyzer (Applera, Cour-
taboeuf, France), as reported elsewhere (Philibert et al., 2010). In
cases of mutation, PCR and sequencing of the DNA sample were
repeated twice to conﬁrm the ﬁnding and rule out any PCR-gen-
erated errors. Every PCR product was sequenced with forward
and reverse primers. The amino acid numbering for the AR was
based on the NCBI reference sequence NM_000044.2 and the AR
database (Gottlieb et al., 2012).
CYP17A1 gene
The CYP17A1 gene was studied when a P450c17 enzymatic
deﬁciency was suspected on the basis of the patient’s hormone
proﬁle. After obtaining informed consent, genomic DNA was
extracted from peripheral leukocytes and then used to perform
PCR exonic ampliﬁcation of the gene, as previously described
(Biason-Lauber et al., 1997). The PCR products were sequenced
using the Big Dye Terminator Cycle Sequencing Kit and analyzed
on an ABI Prism 310 Genetic Analyzer (Applied Biosystems). Ref-
erence Sequence: RefSeq NM_000102.3. Primer sequences are
available upon request.
Concerning the molecular analysis, patient sequences were
compared with the sequence of a control patient with normal XY
DNA.
Expression studies
Expression studies were performed as previously described
(Rosa et al., 2010). Brieﬂy, wild-type CYP17A1 cDNA (originally
from Michael R. Waterman) was inserted into a pcDNA3.1 vector
after addition of an N-terminal myc-tag. Mutant cDNAs were
constructed using the QuikChange II site-directed mutagenesis
kit from Stratagene (La Jolla, CA, USA). Introduction of the
mutations was conﬁrmed by sequencing. Wild-type or mutant
cDNA was transiently transfected into conﬂuent COS-1 cells
using TransFast transfection reagent (32 ll transfection reagent/
3.6 lg DNA). To standardize the steroid production, cells were
cotransfected 1:2 with b-galactosidase (b-gal). Forty-eight hours
after transfection, steroidogenic precursors (progesterone for
17a-hydroxylase activity and 17-OHP for 17,20-lyase activity)
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were added at concentrations of 1.0 lM, which is a concentration
that is close to the Km of this enzyme. Six hours after addition of
the precursor, supernatants were removed and kept frozen at
20 °C until measured. b-gal activity was measured using the b-
galenzyme assay system (Promega Corp., Madison, WI, USA).
The secreted steroids, 17-OHP (reﬂecting 17a-hydroxylase activ-
ity) and DHEA (reﬂecting 17,20-lyase activity), were measured in
duplicate by radioimmunoassay, using commercial kits from
Diagnostic System Laboratories (Morwell Diagnostics, Zurich,
Switzerland). Values were standardized for b-galactivity and
expressed as a percentage of wild-type activity.
To further explore the disease mechanism, we analyzed the
RNA stability of the R239X mutant carrying the premature stop
codon to check for nonsense-mediated decay (NMD). To inhibit
translation, 3 9 107 COS1 cells were pelleted, washed once with
phosphate-buffered saline, and resuspended in medium con-
taining 28 lg of cycloheximide/ml. To subsequently remove the
cycloheximide, the cells were pelleted, washed twice with phos-
phate-buffered saline, and resuspended in medium without the
inhibitor (Rajavel & Neufeld, 2001). The stabilization of RNA was
checked by end-point reverse transcriptase-polymerase chain
reaction (RT-PCR) after RNA extraction, using the RNeasy kit
(Qiagen, Hilden, Germany). Primers and ampliﬁcation condi-
tions are available upon request. GAPDH was used as internal
control.
RESULTS
Over the 3-year study period, 148 boys were referred to our
center for pubertal gynecomastia. Among them, 25 had P/PPG
and were analyzed. The clinical characteristics and BA of these
25 patients are presented in Table 1. The patients’ mean age
(SD) was 14.5  1.1 years at the time of diagnosis (range
12.8–16.5 years) with a mean bone age (SD) of 14.4  1.2 years.
Breast development was scored B3 in 22 patients (88%), all of
whom presented a persistent form of gynecomastia. Only three
patients (patients 23, 24, and 25) had a score of B4. The pubertal
status was scored at Tanner stages 2, 3, 4, and 5, respectively, in
two (8%), nine (36%), 11 (44%), and three (12%) patients.
Obesity was noted for 11 of the boys (44%); seven were grade 1
(28%) and four were grade 2 (16%). The mean BMI (SD) was
23.2  5.2 kg/m2.
The hormonal characteristics of these 25 patients with
prominent and/or persistent pubertal gynecomastia are pre-
sented in Table 2. The endocrine investigations showed
normal FSH and LH secretion in all patients, except patients 19
and 20, who presented high basal gonadotropin levels. The
testosterone level was correlated with the Tanner stage in all
patients, with a mean value of 2.87  1.74 ng/mL. Estradiol
(mean value: 20.29  11.73 pg/mL), prolactin (mean value:
7.85  3.72 ng/mL) and TSH (mean value: 1.92  0.69 mUI/L)
were in the normal range and thus excluded estrogen-secreting
tumor, prolactinoma, and thyroid disorders. Alpha-fetoprotein
(mean value: 1.43  1.01 ng/mL) and hCG (data not shown)
levels were normal in all patients, excluding endocrine tumor.
The very high basal gonadotropin levels in patients 19 and 20,
and the small testis found for these two patients and for patient
21, raised the hypothesis of chromosomal disorders. The kary-
otype was 47,XXY for these three patients, which led to the diag-
nosis of Klinefelter syndrome.
Our attention was drawn by the family history of patients 22,
23, and 24. Two of these patients (23, 24) had the distinction of
being twins and, in addition, their mother complained about
very sparse pubic hair from early puberty. The third patient (22)
had a maternal uncle who presented gynecomastia and never
had children. A p.Ala646Asp mutation in the androgen receptor
gene was found in patients 23 and 24, and this mutation was
Table 1 Clinical characteristics and bone age of the 25 patients with prominent/persistent pubertal gynecomastia (P/PPG). Pubertal status is based on
genital staging
Patient CA (years) BA (years) Height (cm) Weight (kg) BMI (kg/m2) Percentiles
Obesity
grade
Pubertal status
(Tanner stage)
Breast
development
1 14.3 14 175.0 80.0 26.1 >97th 1 4 B3
2 12.8 13 162.0 41.0 15.6 10th 0 3 B3
3 13.5 13 158.5 56.8 22.6 95th 0 2 B3
4 12.8 13 160.5 57.8 22.4 >97th 1 3 B3
5 14.5 17 183.0 109.0 32.5 >97th 2 5 B3
6 14.2 15 174.0 68.0 22.5 95th 0 4 B3
7 13.0 14 169.5 71.0 24.7 >97th 1 4 B3
8 14.6 16 172.5 57.4 19.3 50th 0 5 B3
9 15.8 15 162.8 101.6 38.3 >97th 2 4 B3
10 15.3 14 166.0 52.5 19.0 30th 0 3 B3
11 13.8 13 165.9 63.4 23.0 >97th 1 4 B3
12 14.6 15 176.0 78.0 25.2 >97th 1 4 B3
13 14.8 14 170.0 56.0 19.4 50th 0 3 B3
14 13.9 14 166.0 47.0 17.0 25th 0 4 B3
15 15.3 15 162.3 40.3 15.3 <3th 0 5 B3
16 12.9 13 172.5 81.7 27.5 >97th 2 2 B3
17 15.4 14 165.5 73.7 26.9 >97th 1 3 B3
18 14.8 17 168.2 59.0 20.8 75th 0 3 B3
19 13.7 13 170.0 66.4 23.0 97th 0 3 B3
20 14.1 15 176.0 59.5 19.2 50th 0 3 B3
21 13.6 15 169.0 81.6 29 >97th 2 3 B3
22 15.2 15 178.0 69.5 21.9 75th 0 4 B3
23 16.5 15 176.0 82.6 26.2 >97th 1 4 B4
24 16.5 15 170.5 68.5 23.7 90th 0 4 B4
25 15.4 14 173.5 60.0 20.0 60th 0 4 B4
CA, chronological age; BA, bone age; BMI, body mass index. Patients with genetic defects have been highlighted.
3
ht
tp
://
do
c.
re
ro
.c
h
previously reported in a patient with infertility (Ferlin et al.,
2006) and one with undervirilization (Hiort et al., 1996). Patient
22 presented a new p.Ala45Gly mutation.
The association of low basal T and high basal LH levels in
patient 25 was discordant with his pubertal status, which
prompted us to conduct further endocrine investigations. Most
steroid compounds were evaluated at baseline, as well as after
an ACTH stimulation test (Table 3). We found a clear discrep-
ancy between the high basal progesterone (5-fold above normal
values) and the low basal and non-ACTH stimulated DHEA and
cortisol levels. CYP17A1 gene sequencing revealed compound
heterozygosity consisting of c.275C>A/WT in exon 1 (plus three
known SNPs: rs762163, rs6162, rs6163, all heterozygous) and
c.887C>T/WT in exon 4, respectively, leading to p.Pro35Thr
(P35T) and p.Arg239Stop (R239X) in the P450c17 protein (Fig. 1).
The karyotype was 46,XY.
In order to assess the functional consequences of the muta-
tions, COS1 cells were transfected with the expression vector
pcDNA3 containing either wild-type or mutant CYP17A1 cDNA.
When expressed in the COS1 cells, the mutant protein bearing
the premature stop codon R239X showed a complete loss of 17a-
hydroxylase and 17,20-lyase activity. In contrast, compared with
the wild-type protein, the mutant P35T seemed to retain 15–20%
of 17a-hydroxylase and about 8–10% of 17,20-lyase activity at a
substrate concentration of 1.0 lmol/L (Fig. 2A). To further ana-
lyze the molecular mechanism of the complete loss of function
in the nonsense mutations, we explored the possibility of non-
sense-mediated mRNA decay, NMD, by stabilizing mRNA
through the translation inhibitor cycloheximide, as there is evi-
dence that some mRNA molecules with a premature stop codon
are able to avoid detection and decay (Nagy & Maquat, 1998;
Inacio et al., 2004). However, the normal RNA (WT) was readily
detectable, whereas the RNA derived from the R239X vector was
nearly undetectable and could not be stabilized by cyclohex-
imide (Fig. 2B). This suggests that NMD, and not the production
of a truncated protein, was the reason for the loss of function.
We thus investigated this group of 25 adolescent males with P/
PPG followed at the Pediatric Endocrine Clinic of the Montpel-
lier University Hospital for the last 3 years. Among these
patients, 18 (72%) were diagnosed with ‘idiopathic’ pubertal
gynecomastia. Three patients presented Klinefelter syndrome,
three a PAIS, and the last showed a 17a-hydroxylase/17,20-lyase
deﬁciency. Genetic/hormonal causes therefore concerned 28%
of our patients (95% conﬁdence interval: 10–47).
DISCUSSION
Conversely to prepubertal gynecomastia, which is usually
related to estrogen-producing adrenal or testicular tumors,
pubertal gynecomastia is common, most often idiopathic, and
regresses within a few months to 2 years (Biro et al., 1990; Abaci
& Buyukgebiz, 2007). Nevertheless, drug use, including anabolic
steroids, and endocrine disorders should be considered when it
is prominent (>Tanner B3) and/or persistent (>2 years) (Abaci &
Buyukgebiz, 2007; Ma & Geffner, 2008).
Once drug involvement has been excluded, any endocrine dis-
orders that result in an estrogen/androgen imbalance should be
considered. An excess of estrogen production or a decrease in
the production or action of androgens should be sought. Hyper-
estrogenism may result from excessive tumoral testicular or
adrenal estrogen production. In addition, peripheral estrogen
production may also be related to aromatase excess syndrome
(Fukami et al., 2011).
Regarding the reduction in T production, hypo- or hyperg-
onadotropic hypogonadism may be involved in the development
Table 2 Hormone characteristics of the 25 patients with P/PPG for testosterone (T), estradiol (E2), follicle-stimulating hormone (FSH), luteininzing hormone
(LH), prolactin (PRL) and thyroid-stimulating hormone (TSH)
Patient T (ng/mL)
(N = 3.5–11)
E2 (pg/mL)
(N = 20–60)
T/E2
(N = 175–183)
FSH (UI/L)
(N = 1.5–12)
LH(UI/l)
(N = 1.5–6)
PRL(ng/mL)
(N < 20)
TSH (mUI/L)
(N = 0.1–3.5)
Genetic
defect
1 3.50 19.1 183 3.0 1.3 7.9 2.09
2 2.62 18.2 144 4.3 3.0 8.6 3.05
3 1.06 9.0 118 1.5 1.5 10.2 1.11
4 2.83 9.0 314 0.4 1.8 3.4 2.04
5 4.63 9.2 503 1.4 6.8 7.1 2.18
6 4.69 36.5 128 1.4 2.1 8.7 2.89
7 3.68 20.3 181 2.9 2.2 6.9 1.20
8 8.41 39.0 216 1.3 2.5 5.7 1.80
9 4.35 8.0 544 3.9 2.2 4.2 2.69
10 2.43 13.5 180 3.3 0.8 5.0 2.02
11 2.95 9.5 310 2.3 0.9 5.4 1.37
12 3.84 10.5 366 1.1 0.6 5.1 0.78
13 2.51 9.0 279 1.6 1.9 3.2 1.39
14 4.54 18.5 245 2.2 2.4 6.4 1.62
15 6.20 14.5 428 3.5 2.8 5 3.11
16 1.05 31.9 33 3.1 1.4 4.1 1.75
17 1.63 9.0 181 0.9 1.1 5.7 2.79
18 2.56 12.0 213 3.2 1.9 9.4 1.64
19 1.79 10.0 179 79.9 25.6 13.6 2.65 Klinefelter
20 1.90 36.5 52 43.7 9.3 6.1 1.08 Klinefelter
21 1.46 15 97 10.3 5.1 9 1.20 Klinefelter
22 3.61 20 180 3.8 2.7 12 2.60 AR
23 4.05 16.4 247 1.2 3.4 16 2.30 AR
24 3.76 22 171 2.2 5 16.4 1.10 AR
25 1.60 47.8 33.4 7.5 12 7.7 1.67 CYP17A1
AR, androgen receptor gene mutation, CYP17A1, CYP17A1 gene mutation. N: normal references correspond to normal post-pubertal values. Patients with genetic
defects have been highlighted.
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of gynecomastia (Chan et al., 1999; Narula & Carlson, 2007; Ma
& Geffner, 2008). In addition, pubertal gynecomastia has been
reported as one of the clinical expressions of PAIS (Sultan et al.,
2013).
Over the past several years, the hypothesis has emerged that
environmental endocrine disruptors play a role in the develop-
ment of pubertal gynecomastia through their agonistic action on
ER receptors, as well as antagonistic effects on androgen recep-
tors (Kalyan, 2007; Durmaz et al., 2010).
Exceptional reports of gynecomastia associated with rare
forms of congenital adrenal hyperplasia, including 3-b-hydro-
xysteroid dehydrogenase (Cavanah & Dons, 1993), 11-b-hydroxy-
lase (Hochberg et al., 1991) and, more recently, 21-hydroxylase
deﬁciency (Wasniewska et al., 2008) are still not totally
explained.
The high percentage of ‘idiopathic’ gynecomastia in our
cohort is in agreement with the literature on males at this age
(Ma & Geffner, 2008; Atabek, 2013). It is nevertheless notable
that 7/25 (28%) showed a genetic disorder. Even though this esti-
mation is not precise because of our small sample size (95% con-
ﬁdence interval: 10–47), it suggests that a genetic etiology should
be considered in such patients.
The diagnosis of Klinefelter syndrome in the pubertal period is
unsurprising as most cases are diagnosed at this time (Pacenza
et al., 2012). A low T/E2 ratio is considered to play a key role in
the promotion of breast development (Abdel-Razic et al., 2012).
Gynecomastia is reported in 50–70% of men with Klinefelter syn-
drome and is linked to an increased risk of male breast cancer
(Swerdlow et al., 2005; Narula & Carlson, 2007). Follow-up is
thus necessary for adult patients.
Pubertal gynecomastia in patients with PAIS is well described,
but it is usually associated with signs of undervirilization, such
as micropenis, hypospadias, and cryptorchidism (Sultan et al.,
2013). The three patients with PAIS we report here were nor-
mally virilized, with their androgen resistance expressed exclu-
sively through isolated pubertal gynecomastia. There have been
several reports of pubertal gynecomastia revealing PAIS but in
most cases undervirilzation or infertility was associated (Zen-
teno et al., 2002; Lee et al., 2015; Petroli et al., 2014). Conversely,
the follow-up of PAIS patients revealed the presence of P/PPG in
93% of the cases, but all these patients presented other signs of
undervirilization (Hellmann et al., 2012). The p.Ala646Asp muta-
tion found in our two patients, 23 and 24, has already been
reported in males with undervirilization (Hiort et al., 1996) or
infertility (Ferlin et al., 2006), whereas the Ala45Gly mutation
found in patient 22 has never been reported.
P/PPG has exceptionally occurred in adolescents with congen-
ital adrenal hyperplasia because of 21-hydroxylase, 3-b-hydro-
xysteroid dehydrogenase or 11-b-hydroxylase deﬁciency (Ma &
Geffner, 2008; Wasniewska et al., 2008), but there are no data on
the association of isolated P/PPG and 17a-hydroxylase/17,20-
lyase deﬁciency. In agreement with Martin et al. (Martin et al.,
2003), who reported that basal progesterone measurement was a
useful marker of 17a-hydroxylase/17,20-lyase deﬁciency, we sus-
pected this deﬁciency in patient 25, even in the absence of corti-
costerone and 17hydroxypregnenolone values. To our
knowledge, this is the ﬁrst case of 17a-hydroxylase/17,20-lyase
deﬁciency revealed by pubertal gynecomastia as the only sign of
abnormality, with normal external genitalia and pubertal onset.
Among the approximately 150 cases of 17a-hydroxylase/17,20-
lyase deﬁciency reported in the literature, a 46,XY sex-reversal
was predominant. Most cases have also been diagnosed in child-
hood or adolescence, through apparent mineralocorticoid excess
Table 3 Evaluation of steroid compounds at baseline, as well as after an
ACTH stimulation test for patient 25
Basal values Values/ACTH
Cortisol (μg/dL) 5.6 (N > 12) 7.7
17-OHP (ng/mL) 3.8 4.5 (N < 10 ng/mL)
Prog. (nmol/L) 10.9 (N: 0.7–2) 10.8
DHEA (nmol/L) 1.8 (N: 14  4.5) 2
The steroid compounds evaluated are the following: cortisol, 17 hydroxy proges-
terone (17-OHP), progesterone (Prog) and dehydroepiandrosterone (DHEA). The
units are speciﬁed in brackets. N: normal references correspond to normal post-
pubertal values.
Figure 1 Sequence analysis of the CYP17A1
gene in control and patient 25. Arrows point out
the amino acid substitutions in the patient com-
pared with the control.
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with salt retention and hypertension associated or not with
delayed puberty (Miller, 2004). In addition, partial forms of 17a-
hydroxylase/17,20-lyase deﬁciency in undervirilized 46,XY
patients have been reported (Biason-Lauber et al., 2000; Van
Den Akker et al., 2002; Martin et al., 2003; Costa-Santos et al.,
2004; Idkowiak et al., 2012). The absence of genital abnormality
in our patient is unusual and indicates the likelihood of a slight
enzymatic deﬁciency. Mild forms of 17a-hydroxylase/17,20-
lyase deﬁciency have exceptionally been reported in 46,XY
patients (New, 1970; Bosson et al., 1988; de Lange & Doorenbos,
1990), two of whom were investigated for persistent gynecomas-
tia (New, 1970; de Lange & Doorenbos, 1990). Conversely to the
patient we report here, these patients presented no spontaneous
pubertal development (de Lange & Doorenbos, 1990) or
undervirilization (New, 1970). Although the direct relationship
between the development of gynecomastia and the 17a-hydro-
xylase/17,20-lyase deﬁciency cannot be proven, it is likely that
the androgen defect modiﬁes the T/E balance, promoting breast
development (New, 1970; de Lange & Doorenbos, 1990). In two
46,XY patients with very partial forms of 17a-hydroxylase/17,20-
lyase deﬁciency (Bosson et al., 1988; de Lange & Doorenbos,
1990), as in our patient, no hypertension was found, whereas
slightly elevated blood pressure was noted in the patient
reported by New (New, 1970).
Conversely to these three very slight enzymatic defects with a
diagnosis only biologically established, the endocrine investiga-
tions in our patient (25) suggested a 17a-hydroxylase/17,20-lyase
deﬁciency and this was conﬁrmed by molecular analysis: we
identiﬁed a double heterozygous mutation: p.P35T and p.R239X.
To our knowledge, the p.P35T mutation of P450c17 has never
been reported, whereas p.R239X was reported in a male patient
with ambiguous genitalia who presented a p.P342T on the other
allele (Ahlgren et al., 1992). In order to conﬁrm the causative role
of these two mutations, functional analysis was performed. In
transfected COS1 cells, the mutant protein bearing the prema-
ture stop codon R239X showed complete losses in 17a-hydroxy-
lase and 17,20-lyase activity, as to be expected, whereas the
mutant P35T seemed to retain 15–20% of 17a-hydroxylase and
8–10% of 17,20-lyase activity. The preservation of residual 17a-
hydroxylase and 17,20-lyase activity is in agreement with the
partial phenotype. The low T level related to a T biosynthesis
defect, with a T/E2 imbalance, contributed to the breast devel-
opment in our patient. After surgical removal of gynecomastia,
adequate treatment with hydrocortisone and testosterone was
introduced to prevent hypertension and achieve normal puberty.
Despite oligospermia, sperm cryoconservation was performed.
Several study limitations must be acknowledged. First, as a
result of the exploratory and descriptive nature of the study, the
sample size was not sufﬁcient to estimate precisely the preva-
lence of endocrine/genetic causes among the P/PPG population.
Moreover, we cannot exclude a selection bias, as many adoles-
cents do not consult for pubertal gynecomastia or only consult
their general practitioner. The patients referred to our special-
ized center may therefore have been among the most serious
cases.
In conclusion, our work showed that 28% of the cases of P/
PPG in the adolescent males followed in our clinic had an endo-
crine/genetic cause. PAIS and 17a-hydroxylase/17,20-lyase deﬁ-
ciency may both be revealed by isolated P/PPG as the only
clinical expression. Isolated P/PPG is not always a ‘physiological’
condition and should thus be investigated by endocrine and
genetic evaluations, even though larger studies are needed to
better determine the real prevalence of genetic defects in such
patients.
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